Catalog Advanced Search

Search by Category
Search by Format
Search by Type
Search by Speakers
Credits Offered
Search in Packages
Search by Date Range: Start

End
Search by Favorites
Search by Keyword
Sort By

CE Credit available

2025 ACMT Psychedelics Seminar

Contains 5 Component(s), Includes Credits

Component	Credit Type	State/Medical Type	Available Credits
Continuing Education Certificate	Medical	Physician (CME)	10.00
Continuing Education Certificate	Medical	Nurse (CNE)	10.00
Continuing Education Certificate	Medical	Pharmacist (CPE)	10.00

Includes Multiple Live Events. The next is on 10/10/2025 at 10:00 AM (EDT)

October 10 & 17, 2025

ACMT Psychedelics Seminar

Fridays in October 2025: 10/10 & 10/17
10-3:45pm ET, Virtual Course, Live Zoom Event

Explore the evolving science, clinical applications, and complex realities of psychedelics in the 2025 ACMT Psychedelics Seminar, a two-day virtual course designed for healthcare professionals, clinicians, and toxicologists.

Held over two Fridays in October, this immersive course provides a comprehensive foundation in the pharmacology, toxicology, and therapeutic uses of psychedelics, while critically examining their place in today’s healthcare landscape.

Course Themes:

Psychedelics 101: Pharmacology & Foundations
Clinical Applications
Adverse Effects & Safety
Policy, Ethics & Real-World Implementation

Over two days, participants will explore the pharmacology of classic psychedelics—including psilocybin, ayahuasca, mescaline, and LSD—as well as the therapeutic potential of ketamine, ibogaine, MDMA, and other novel psychotherapies. The course will review current evidence on psychedelics for treating substance use disorders, depression, PTSD, anxiety, and emerging areas such as dementia and Parkinson’s disease. Sessions will address the shifting legal and regulatory landscape, highlighting lessons from Oregon and Colorado’s psilocybin programs, the rapid growth of ketamine clinics, and the realities of microdosing.

Throughout the seminar, faculty will emphasize safety, adverse effects, drug interactions, and emerging designer substances, while engaging participants in critical conversations about indigenous knowledge, ethical access, and responsible integration of psychedelics into modern healthcare.

Registration for this activity includes two-days of live virtual event programming, 90 day access to the on-demand recordings after the live event, and 10.0 Continuing Education credits.

Target Audience

This seminar is designed for healthcare professionals and researchers interested in medical toxicology, addiction medicine and the emerging role of psychedelics in therapeutic settings, including:

Physicians
Pharmacists
Nurses and Nurse Practitioners
Physician Assistants
Clinicians and Specialists in Poison Information
Addiction Counselors and Mental Health Professionals
Researchers
Fellows, Residents, and Students

Continuing Education

Live and Enduring continuing education credits for Physicians, Pharmacists, and Nurses is provided by AKH Inc., Advancing Knowledge in Healthcare. It is expected that learners will receive up to 10.0 credits for learning and change.

Learner Objectives

After Completing This Program You Should Be Able To:

Describe the pharmacology and toxicology of classic and emerging psychedelics, including psilocybin, ketamine, ibogaine, and MDMA.
Evaluate current research on the clinical use of psychedelics in treating substance use disorders, mental health conditions, palliative care, and special populations.
Analyze the adverse effects and safety considerations associated with psychedelic use.
Identify practical strategies, legal factors, ethical considerations, and systemic barriers to integrating psychedelic-assisted therapies into existing treatment frameworks.

Questions?

Please write to ACMT at events@acmt.net

Registration Rates

Registration includes:

Access to the live virtual events on October 10, 2025 and October 17, 2025

Access to the on-demand recording for 90 days after the live virtual events

Access to the speaker slides

10.0 Continuing Education credits for Physicians (CME), Pharmacists (CPE) or Nurses (CNE)

Member Rates

Member Tier I: Full, Affiliate, International, Emeritus	$350
Member Tier II: Fellows	$300
Member Tier III: Residents, International - Developing Country	$250
Member IV: Medical Students	$200

Non-Member Rates

Non-member Tier I: Physicians, Pharmacists, Lawyers, "Other"	$450
Non-member Tier II: Fellows, SPIs, Nurses, etc.	$400
Non-member Tier III: Educators & Emergency Responders	$350
Non-member IV: Residents & Students	$300

ACMT Membership

ACMT Members receive a discounted rate. Interested in becoming an ACMT Member? Contact our Membership Team at membership@acmt.net. Learn more at: www.acmt.net/membership

Refunds and Cancellations

For information on ACMT's Cancellation and refund policy, click here.

Questions?

For any questions, please email us at events@acmt.net.

This agenda is preliminary and subject to change. Speakers will be added as they confirm their participation. For the convenience of attendees from around the country, all times zones are listed -- please make sure you are looking at your correct time zone.

Friday, October 10, 2025

7:00-7:15 AM PT | 8:00-8:15 AM MT | 9:00-9:15 AM CT | 10:00-10:15 AM ET

Welcome & Opening Remarks

7:15-8:15 AM PT | 8:15-9:15 AM MT | 9:15-10:15 AM CT | 10:15-11:15 AM ET

Classic Psychedelics (Psilocybin, Ayahuasca, Mescaline & LSD) and Beyond (Ketamine, Ibogaine, MDMA & Novel Psychotherapies)

Joshua Woolley, MD, PhD, Associate Professor of Psychiatry, UCSF Weill Institute for Neurosciences, University of California, San Francisco

8:15-9:15 AM PT | 9:15-10:15 AM MT | 10:15-11:15 AM CT | 11:15-12:15 PM ET

Treating Substance Use Disorders: Emerging Evidence and Approaches

9:15-9:30 AM PT | 10:15-10:30 AM MT | 11:15-11:30 AM CT | 12:15-12:30 PM ET

Break

9:30-10:30 AM PT | 10:30-11:30 AM MT | 11:30-12:30 PM CT | 12:30-1:30 PM ET

Mental Health Breakthroughs: Psychedelics in Depression, PTSD & Anxiety

10:30-11:00 AM PT | 11:30-12:00 PM MT | 12:30-1:00 PM CT | 1:30-2:00 PM ET

Psychedelics and the Management of Acute Suicidal Ideation

Anthony F. Pizon, MD, Chief, Division of Medical Toxicology, Department of Emergency Medicine, Professor, University of Pittsburgh School of Medicine

11:00-11:15 AM PT | 12:00-12:15 PM MT | 1:00-1:15 PM CT | 2:00-2:15 PM ET

Break

11:15-11:45 AM PT | 12:15-12:45 PM MT | 1:15-1:45 PM CT | 2:15-2:45 PM ET

Psychedelics & Neurodegeneration

Albert Garcia-Romeu, PhD, Associate Professor, Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine

11:45-12:15 PM PT | 12:45-1:15 PM MT | 1:45-12:15 PM CT | 2:45-3:15 PM ET

At Life's Edge: Psychedelic Use in Palliative and End-of-Life Care

Benjamin Hatten, MD, MPH, Medical Toxicologist, Toxicology Associates & Associate Professor of Emergency Medicine, University of Colorado

12:15-12:45 PM PT | 1:15-1:45 PM MT | 2:15-2:45 PM CT | 3:15-3:45 PM ET

Advancing Psychedelic Science: Novel Molecules, New Mechanisms

Alex Kwan, PhD, Associate Professor, Meinig School of Biomedical Engineering, Cornell University

Friday, October 17, 2025

7:00-7:15 AM PT | 8:00-8:15 AM MT | 9:00-9:15 AM CT | 10:00-10:15 AM ET

Welcome & Opening Remarks

7:15-8:00 AM PT | 8:15-9:00 AM MT | 9:15-10:00 AM CT | 10:15-11:00 AM ET

Proceed with Caution: Adverse Effects, Drug Interactions & Designer Psychedelics

Shana Kusin, MD, Associate Professor of Emergency Medicine, Oregon Health & Science University

8:00-8:45 AM PT | 9:00-9:45 AM MT | 10:00-10:45 AM CT | 11:00-11:45 AM ET

The Wild West of Ketamine: Safety and Health Equity Concerns Surrounding the Use of Ketamine for Psychiatric Conditions

Arielle Graham, MD, Associate Psychiatrist, Brigham and Women’s Hospital; Instructor, Harvard Medical School
Powell Graham, MD, Assistant Professor of Emergency Medicine, UMass Chan Medical School; Director of Outpatient Toxicology Services, UMass Memorial Health
Jeffrey Lai, MD, Assistant Professor and Fellowship Director, UMass Chan Medical School

8:45-9:30 AM PT | 9:45-10:30 AM MT | 10:45-11:30 AM CT | 11:45-12:30 PM ET

Microdosing and the Mainstream: Real-World Use Beyond the Hype

Sandeep Nayak, MD, Psychiatrist, Assistant Professor, Center for Psychedelic and Consciousness Research, Johns Hopkins

9:30-9:45 AM PT | 10:30-10:45 AM MT | 11:30-11:45 AM CT | 12:30-12:45 PM ET

Break

9:45-10:15 AM PT | 10:45-11:15 AM MT | 11:45-12:15 PM CT | 12:45-1:15 PM ET

The Legal Landscape: Psychedelics in Policy and Practice Today

Mason Marks, MD, JD, Florida Bar Health Law Section Professor, Florida State University

10:15-10:45 AM PT | 11:15-11:45 AM MT | 12:15-12:45 PM CT | 1:15-1:45 PM ET

Regulatory Realities: Navigating FDA Approval and DEA Scheduling of Psychedelics

10:45-11:30 AM PT | 11:45-12:30 PM MT | 12:45-1:30 PM CT | 1:45-2:30 PM ET

Indigenous Knowledge & Ethical Access: Rights, Reciprocity & Respect

11:30-11:45 AM PT | 12:30-12:45 PM MT | 1:30-1:45 PM CT | 2:30-2:45 PM ET

Break

11:45-12:45 PM PT | 12:45-1:45 PM MT | 1:45-2:45 PM CT | 2:45-3:45 PM ET

The Oregon & Colorado Models: Lessons from the First State-Regulated Psilocybin Markets

Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT (Moderator)

Emergency Medicine Attending Physician, Professor Of Emergency Medicine, Co-Medical Director

MedStar Washington Hospital Center, Georgetown University Hospital, National Capital Poison Center

Dr. Maryann Amirshahi is a Professor of Emergency Medicine at Georgetown University School of Medicine and practices clinically at MedStar Washington Hospital Center, where she specializes in toxicology, addiction care, and emergency medicine. She holds a PharmD and medical degree, alongside an MPH focusing on environmental and occupational health, and a PhD in pharmacology and public health. Dr. Amirshahi is board-certified in emergency medicine, medical toxicology, addiction medicine, and clinical pharmacology, and is a registered pharmacist with over a decade of practice. Nationally recognized, she serves on the Board of Directors for the American College of Medical Toxicology and as co-medical director of the National Capital Poison Center. With nearly 200 peer-reviewed publications, her research spans medication safety, drug shortages, addiction treatment, and prescription drug misuse.

Albert Garcia-Romeu, PhD

Associate Professor, Behavioral Pharmacology Research Unit

Johns Hopkins University

Albert Garcia-Romeu, PhD, is an Associate Professor of Psychiatry and Behavioral Sciences at the Johns Hopkins University School of Medicine. His research examines the effects of psychedelics in humans, with a focus on psilocybin as an aid in the treatment of addiction. His current research interests include clinical applications of psychedelics, real-world drug use patterns, diversity in science, and the role of spirituality in mental health. He is a founding member of the Johns Hopkins Center for Psychedelic and Consciousness Research and the International Society for Research on Psychedelics. He serves on the Board of Directors for the College on Problems of Drug Dependence (CPDD) and is an Associate Editor for the journal Psychedelic Medicine.

Arielle Graham, MD

Associate Psychiatrist & Instructor

Brigham and Women’s Hospital & Harvard Medical School

Dr. Graham is double board-certified (adult and child/adolescent) psychiatrist with expertise in young adult mental health, emergency mental health, consultation-liaison psychiatry, medical education/training, clinical informatics and medical writing/editing. She completed her psychiatry residency and child and adolescent psychiatry fellowship at UMass Chan Medical School, following which she worked as an attending psychiatrist at UMass Memorial Medical Center and an Assistant Professor of Psychiatry and Pediatrics at UMass Chan Medical School. She is currently an Associate Psychiatrist at Brigham and Women’s Hospital and a Clinical Instructor in Psychiatry at Harvard Medical School.

Powell Graham, MD

Assistant Professor of Emergency Medicine

University of Massachusetts Chan Medical School

Dr. Graham works as a board-certified medical toxicologist and an emergency medicine physician at UMass Chan Medical School in Worcester, MA. There, he is also the director of the outpatient toxicology clinic. He acts as an educator, clinician, and researcher in these capacities. He completed his toxicology fellowship in 2022 at UMass after completing his residency in emergency medicine also at UMass. His current academic and research interests include psychedelics, addiction medicine, cannabinoids, and harm reduction.

Benjamin Hatten, MD, MPH

Medical Toxicologist, Toxicology Associates & Associate Professor of Emergency Medicine

University of Colorado

Dr. Ben Hatten is an Assistant Professor in the Department of Emergency Medicine at the University of Colorado School of Medicine, with a primary appointment in the Section of Medical Toxicology. He is also an attending physician at the Rocky Mountain Poison and Drug Center and serves as faculty for the Emergency Medicine Residency, Occupational Medicine Residency, and Medical Toxicology Fellowship programs in Denver. Board certified in both emergency medicine and medical toxicology, Dr. Hatten actively practices in both fields. He earned his M.D. from the University of Texas Southwestern Medical Center and completed his emergency medicine residency at Denver Health Medical Center. He went on to complete a Medical Toxicology Fellowship at Oregon Health & Science University, where he also earned an M.P.H. in epidemiology and biostatistics. Since returning to Denver in 2013, he has been a key contributor to toxicology education, research, and clinical care across multiple institutions.

Robert Hendrickson, MD, FACMT (Moderator)

Professor of Emergency Medicine, Medical Director, Program Director

Oregon Health and Science University, Oregon Poison Center, OHSU Fellowship in Medical Toxicology

Dr. Rob Hendrickson graduated from the State University of New York, Downstate College of Medicine, and completed training in Emergency Medicine and Medical Toxicology at the Medical College of Pennsylvania. He is a Professor of Emergency Medicine at Oregon Health and Sciences University where he is Chief of the Section of Medical Toxicology, Program Director for the fellowship in medical toxicology, and the Medical Director of the Oregon Poison Center.

Shana Kusin, MD, FACMT (Moderator)

Associate Professor of Emergency Medicine

Oregon Health & Science University

Dr. Shana Kusin is an Associate Professor of Emergency Medicine at Oregon Health & Science University (OHSU), where she has served as full-time faculty since 2013 following her fellowship in Medical Toxicology at OHSU and the Oregon Poison Center. She sees patients in both the OHSU and Doernbecher Emergency Departments. Dr. Kusin’s academic interests center on medical toxicology—particularly drugs of abuse and plant- and animal-based toxins—as well as leveraging electronic health records to improve community-wide healthcare through information sharing and clinical decision support.

Alex Kwan, PhD

Associate Professor, Meinig School of Biomedical Engineering

Cornell University

Dr. Alex Kwan is a neuroscientist and Associate Professor at Cornell University, where he leads a research lab focused on uncovering how psychiatric drugs affect brain function and behavior. He earned his Ph.D. in applied physics from Cornell and completed postdoctoral training in neuroscience at UC Berkeley. Before returning to Cornell in 2022, he was a faculty member in the Department of Psychiatry at Yale School of Medicine. Dr. Kwan’s lab combines systems neuroscience, optical imaging, and behavioral paradigms in animal models to study how compounds like ketamine and serotonergic psychedelics alter neural circuits to produce therapeutic effects. His long-term goal is to develop effective and safe treatments for depression by leveraging neurobiological insights into drug action.

Jeffrey Lai, MD

Assistant Professor and Director, Medical Toxicology Fellowship

UMass Chan Medical School

Jeffrey Lai, MD, is an emergency physician and medical toxicologist. He completed his undergraduate studies at the University of California, Berkeley; medical school at the University of Pittsburgh; and emergency medicine residency and medical toxicology fellowship at the University of Massachusetts. He is the program director of the medical toxicology fellowship at UMass Chan Medical School, and his academic interests include medical education, the application of novel technologies to the treatment of substance use disorders, and the surveillance of impairing substances in patients with severe traumatic injurie

Sandeep Nayak, MD

Psychiatrist, Assistant Professor, Center for Psychedelic and Consciousness Research

Johns Hopkins University

Dr. Sandeep Nayak is a psychiatrist and Assistant Professor at the Center for Psychedelic and Consciousness Research at Johns Hopkins University. He earned his medical degree from Brown University and completed his psychiatry residency at Johns Hopkins Hospital. His research focuses on the use of psychedelics to treat psychiatric conditions, particularly substance use and mood disorders, with additional interests in psychedelic-induced belief change and the application of Bayesian statistics to clinical trials. In addition to his research, Dr. Nayak provides clinical care at Addiction Treatment Services (ATS) and the Center for Addiction and Pregnancy (CAP) at Johns Hopkins Bayview Medical Center.

Mason Marks, MD, JD

Florida Bar Health Law Section Professor

Florida State University

Dr. Mason Marks is the Florida Bar Health Law Section Professor at Florida State University College of Law and a leading expert on drug policy, health law, and the regulation of psychedelics. He is a Senior Fellow at Harvard Law School’s Petrie-Flom Center, where he co-founded and directs the Project on Psychedelics Law and Regulation (POPLAR), and a Visiting Fellow at Yale Law School’s Information Society Project. With dual degrees in medicine and law, Dr. Marks publishes widely on drug regulation, constitutional rights, and the intersection of AI, health, and free thought, with scholarship appearing in top law reviews and medical journals such as JAMA, Nature Medicine, and The New England Journal of Medicine. His work has been cited by the U.S. Court of Appeals, the U.S. Senate, the WHO, and the FTC, and featured in major media outlets including The New York Times, NPR, and The Economist. A sought-after speaker and advisor, Dr. Marks regularly briefs state and federal agencies on controlled substances policy and teaches courses on constitutional, administrative, health, and psychedelic law. He holds degrees from Amherst College (BA), Tufts University (MD), and Vanderbilt University (JD).

Anthony Pizon, MD, FACMT

Chief of Medical Toxicology Division, Professor of Emergency Medicine

University of Pittsburgh

Dr. Anthony (Tony) Pizon received his medical degree from the University of Toledo School of Medicine in 2001. He then completed his Emergency Medicine Residency at the University of Pittsburgh Medical Center in 2004 and his Medical Toxicology Fellowship at Banner Good Samaritan Medical Center in Phoenix, Arizona in 2006. Dr. Pizon is currently a Professor in the Department of Emergency Medicine, Division of Medical Toxicology at the University of Pittsburgh, School of Medicine. He serves as Chief of the Division of Medical Toxicology and Director of the Medical Toxicology Fellowship at UPMC. He is also Assistant Medical Director of both the Pittsburgh and West Virginia Poison Centers. Yet, most importantly, he is blessed with amazing wife, Caryn, and four wonderful children (Benjamin, Elizabeth, Gabriela, and Seraphina).

Evan Schwarz, MD, FACMT (Moderator)

Associate Professor of Emergency Medicine

University of California, Los Angeles

Dr. Evan Schwarz attended medical school at the University of Texas Medical Branch in Galveston, Texas, before completing a residency in Emergency Medicine at the Washington University School of Medicine in Saint Louis, Missouri. After residency, he completed a fellowship in Medical Toxicology at the University of Texas Southwestern School of Medicine in Dallas, Texas, before returning to Missouri where he was an Advisory Dean and the Medical Toxicology Division Chief and Fellowship Director at Washington University. In 2023, he took a position in the Department of Emergency Medicine at the University of California Los Angeles. He is also a member of the Board of Directors for ACMT.

Joshua Woolley, MD, PhD

Associate Professor of Psychiatry, UCSF Weill Institute for Neurosciences

University of California, San Francisco

Dr. Josh Woolley is a nationally recognized leader in psychedelic science and psychiatric research. He serves as Associate Professor of Psychiatry at UCSF and Director of the Translational Psychedelic Research (TrPR) Program, where he leads groundbreaking studies on the safety, efficacy, and therapeutic mechanisms of compounds such as psilocybin, MDMA, and ketamine for treating neuropsychiatric disorders. A board-certified psychiatrist and staff physician at the San Francisco VA, Dr. Woolley also serves as Associate Director of its Psychosis Clinic and has played a key role in training the next generation of clinicians and researchers. He has mentored over 30 postdocs and 8 junior faculty, co-directed UCSF’s foundational psychiatry course, and earned multiple accolades for his excellence in teaching and research. His work is supported by the VA, Department of Defense, philanthropic foundations, and industry, and has been published in top-tier journals including JAMA, Nature Neuroscience, and Biological Psychiatry.

Instructions

Once you have completed your registration:

Click on the Contents tab and attend the live events.
Complete the Post-Test. These questions are based on content from the lectures to gauge your comprehension. It requires a 80% to pass.
Complete the CE Survey. These questions are required to claim your CE certificate.
Claim your CE certificate. Once you have claimed your CE credit, you will not be able to change your CE certificate.

Full credit can only be claimed after completion of all required components.

Hardware/Software Requirements

Computer or Other Internet-Enabled Device; Internet Connection; Browser.

Materials

None.

Prerequisites

None.

Format

This is a live, virtual course.

Need Assistance or Have Questions?

For assistance logging in, accessing content, purchasing or completing Continuing Education credits, or for other questions, please contact us at events@acmt.net or visit our FAQ page.

If you are in need of accessible learning accommodations, please contact events@acmt.net for additional assistance.

Continuing Education

2025 ACMT Psychedelics Seminar, Live Virtual Event
Please claim your continuing education credits within 30 days of the live event: November 17, 2025

CE credit provided by AKH Inc., Advancing Knowledge in Healthcare.

Criteria for Success
To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate. You must participate in the entire activity to receive credit. There is no fee to participate in this activity. If you have questions about this activity, please contact AKH Inc. at events@acmt.net. If you have questions about this CE activity, please contact AKH Inc at bethany@akhcme.com

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 10.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians: AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 10.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses: Credit being awarded: 10.0 ANCC contact hours.

Pharmacists: AKH Inc., Advancing Knowledge in Healthcare designates this continuing education activity for 10.0 contact hours.

Register
- Non-member - Tier I - $450
- Non-member - Tier II - $400
- Non-member - Tier III - $350
- Non-member - Tier IV - $300
- Member - Tier I - $350
- Member - Tier II - $300
- Member - Tier III - $250
- Member - Tier IV - $200
Continue
More Information

National Grand Rounds - October 2025

Contains 4 Component(s) Includes a Live Web Event on 10/07/2025 at 12:00 PM (EDT)

Gadolinium Deposition Disease

Gadolinium Deposition Disease

Join ACMT on Tuesday, October 7, 2025, at 12 PM ET for an exclusive National Grand Rounds featuring Dr. Brent Wagner. A leading expert in nephrogenic systemic fibrosis and gadolinium retention, Dr. Wagner will share insights from his groundbreaking research on Gadolinium Deposition Disease, a condition linked to the use of MRI contrast agents in patients with impaired renal function. This session will explore the clinical implications, pathophysiology, and evolving understanding of gadolinium-related complications.

About The Series: ACMT's Grand Rounds offer an in-depth and interactive platform for learning and discussion about issues that impact the research and practice of medical toxicology. Experts from within and outside medical toxicology will share their knowledge and experience and highlight areas for collaboration and mutual understanding.

This webinar is for ACMT members only.

Brent Wagner, MD, MS

Associate Professor of Nephrology

University of New Mexico Health Science Center

Dr. Brent Wagner is a board-certified specialist in Internal Medicine and Nephrology, with a distinguished career in clinical care, research, and medical education. A native of New Mexico, he earned his undergraduate, graduate, and medical degrees from the University of New Mexico, and completed his residency on the ABIM Research Investigator Pathway at the University of Texas Health System. He previously served as Clinical Nephrology Fellowship Program Director and staff nephrologist at the Audie Murphy Memorial VA Hospital, and became a tenured Associate Professor in 2017. In 2018, he returned to Albuquerque to lead the Renal Section at the New Mexico VA Health Care System and direct the Kidney Institute of New Mexico. An internationally recognized expert in nephrogenic systemic fibrosis, gadolinium retention, and nanotoxicology, Dr. Wagner’s pioneering research has advanced understanding of the molecular and cellular effects of MRI contrast agents.

Nicholas E. Nacca, MD, FACMT (Moderator)

Assistant Professor of Emergency Medicine, Director of Medical Toxicology, Fellowship Director of Medical Toxicology Fellowship Program

University of Rochester Medical Center

Dr. Nicholas Nacca is the director of Medical Toxicology and Medical Toxicology Fellowship Director at the University of Rochester Medical Center. In addition to being faculty member in the Department of Emergency Medicine he holds a secondary appointment in the Department of Environmental Medicine. His primary role is staffing the educational and clinical medical toxicology consultation service, with educational responsibilities to medical toxicology fellows, multidisciplinary teams of medical residents, pharmacy residents and students, as well as medical students. He staffs and directs a referral based outpatient Medical Toxicology Clinic.
- Register
  Member - Tier I - Free!
  
  Member - Tier II - Free!
  
  Member - Tier III - Free!
  
  Member - Tier IV - Free!
  
  Continue
- More Information
CE Credit available

Addiction Toxicology Case Conference - October 2025

Contains 5 Component(s) Includes a Live Web Event on 10/03/2025 at 1:00 PM (EDT)

Topic coming soon!

This month's topic to be announced soon!

Friday, October 3, 2025
1:00-2:00pm ET
Case 1: TBA

Case 2: TBA

Learning Objectives

TBA

Continuing Education

1.25 Continuing Education credits for Physicians and Nurses available ($20 certificate fee). Click here for more info.

About The Series: The ACMT/ASAM Addiction Toxicology Case Conference webinar series discusses Addiction/Toxicology cases in an interactive fashion featuring experts from Addiction Medicine, Addiction Psychiatry, and Medical Toxicology.

This webinar is free and open to the public.

Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)

Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center

ASAM President Elect (2025-2027)

Dr. Tim Wiegand is an Associate Professor of Emergency Medicine and Public Health Sciences at the University of Rochester Medical Center (URMC) in Rochester, New York. Board-certified in both Medical Toxicology and Addiction Medicine, Dr. Wiegand specializes in Addiction Toxicology, combining clinical practice with research, teaching, and leadership roles. He has served two terms on the Board of Directors for the American College of Medical Toxicology (ACMT) and is currently on the Board of Directors for the American Society of Addiction Medicine (ASAM). From 2023-2025, he served as Treasurer of ASAM, having previously served as Vice President on the Executive Council. From 2025-2027, Dr. Wiegand will serve as ASAM President Elect and then ASAM President (2027-2029). Dr. Wiegand founded and led the Toxicology Service at URMC until 2022, when he transitioned to Director of Addiction Medicine and Director of Addiction Medicine Consults in the Department of Emergency Medicine. He also serves as Fellowship Director for the URMC Combined Addiction Medicine Fellowship and is leading efforts to launch the URMC Medical Toxicology Fellowship, which is expected to be formally accredited by July 2023.

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Since 1986, Dr. Gloria Baciewicz has specialized in the treatment of addiction. Professor of clinical psychiatry at the University of Rochester Medical Center, she serves as an addiction psychiatrist at Strong Recovery. Dr. Baciewicz is certified in addiction medicine by the American Board of Preventive Medicine and board certified in psychiatry, with added qualifications in addiction psychiatry. Dr. Baciewicz is a co-principal investigator for the University of Rochester’s Recovery Center of Excellence.

Continuing Education

Continuing Education credit for this activity is provided by AKH Inc., Advancing Knowledge in Healthcare, and is available for an additional fee ($20 administrative fee per certificate).

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and American College of Medical Toxicology (ACMT). AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

This activity was planned by and for the healthcare team, and learners will receive 1.25 Interprofessional Continuing Education (IPCE) credit for learning and change.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live virtual and enduring activity for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. For physicians, hours of participation are the number of AMA PRA Category 1 Credit(s)™ awarded.

Nurses
Credit being awarded: 1.25 ANCC contact hours.

Commercial Support
There is no commercial support for this activity.

Timothy J. Wiegand, MD, FACMT, DFASAM, Lead Physician Planner/Reviewer/Faculty: has nothing to disclose.
Gloria J. Baciewicz, MD, Physician Planner/Reviewer/Faculty: has nothing to disclose.

ACMT Planners and Reviewers: have nothing to disclose.
AKH Planners and Reviewers: have nothing to disclose.

None of the planners or faculty for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

All of the relevant financial relationships listed for these individuals have been mitigated.

Disclosures

It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use and Investigational Product

This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaim responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participants misunderstanding of the content. If you would like to opt out from future communications from AKH please send an email to optout@akhcme.comwith your information with "Opt Out" in the subject line.
- Register
  Non-member - Tier I - Free!
  
  Non-member - Tier II - Free!
  
  Non-member - Tier III - Free!
  
  Non-member - Tier IV - Free!
  
  Member - Tier I - Free!
  
  Member - Tier II - Free!
  
  Member - Tier III - Free!
  
  Member - Tier IV - Free!
  
  Continue
- More Information

Catalog Advanced Search

National Case Conference - December 2025

ACMT National Case Conference

Joshua D. King, MD, FACMT (Moderator)

Associate Professor, Medicine and Pharmacy; Medical Director, Maryland Poison Center

University of Maryland School of Medicine

National Grand Rounds - December 2025

Topic TBA

Nicholas E. Nacca, MD, FACMT (Moderator)

Assistant Professor of Emergency Medicine, Director of Medical Toxicology, Fellowship Director of Medical Toxicology Fellowship Program

University of Rochester Medical Center

Addiction Toxicology Case Conference - December 2025

This month's topic to be announced soon!

Learning Objectives

Continuing Education

Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)

Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center

ASAM President Elect (2025-2027)

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Continuing Education

National Case Conference - November 2025

ACMT National Case Conference

Joshua D. King, MD, FACMT (Moderator)

Associate Professor, Medicine and Pharmacy; Medical Director, Maryland Poison Center

University of Maryland School of Medicine

National Journal Club - November 2025

This month's theme coming soon!

Steven E. Aks, DO, FACMT (Moderator)

Toxicology Director and Professor of Emergency Medicine

Rush Medical College

Addiction Toxicology Case Conference - November 2025

This month's topic to be announced soon!

Learning Objectives

Continuing Education

Timothy Wiegand, MD, DFASAM, FACMT, FAACT (Moderator)

Director of Addiction Medicine and Addiction Medicine Consults, University of Rochester Medical Center

ASAM President Elect (2025-2027)

Gloria Baciewicz, MD (Moderator)

Addiction Psychiatrist

Strong Recovery

Continuing Education

National Case Conference - October 2025

ACMT National Case Conference

Joshua D. King, MD, FACMT (Moderator)

Associate Professor, Medicine and Pharmacy; Medical Director, Maryland Poison Center

University of Maryland School of Medicine

2025 ACMT Psychedelics Seminar

ACMT Psychedelics Seminar

Target Audience

Continuing Education

Learner Objectives

Questions?

Registration Rates

Member Rates

Non-Member Rates

ACMT Membership

Refunds and Cancellations

Questions?

Welcome & Opening Remarks

Classic Psychedelics (Psilocybin, Ayahuasca, Mescaline & LSD) and Beyond (Ketamine, Ibogaine, MDMA & Novel Psychotherapies)

Treating Substance Use Disorders: Emerging Evidence and Approaches

Mental Health Breakthroughs: Psychedelics in Depression, PTSD & Anxiety

Psychedelics and the Management of Acute Suicidal Ideation

Psychedelics & Neurodegeneration

At Life's Edge: Psychedelic Use in Palliative and End-of-Life Care

Advancing Psychedelic Science: Novel Molecules, New Mechanisms

Friday, October 17, 2025

Welcome & Opening Remarks

Proceed with Caution: Adverse Effects, Drug Interactions & Designer Psychedelics

The Wild West of Ketamine: Safety and Health Equity Concerns Surrounding the Use of Ketamine for Psychiatric Conditions

Microdosing and the Mainstream: Real-World Use Beyond the Hype

The Legal Landscape: Psychedelics in Policy and Practice Today

Regulatory Realities: Navigating FDA Approval and DEA Scheduling of Psychedelics

Indigenous Knowledge & Ethical Access: Rights, Reciprocity & Respect

The Oregon & Colorado Models: Lessons from the First State-Regulated Psilocybin Markets

Maryann Amirshahi, PharmD, MD, MPH, PhD, FACMT (Moderator)

Emergency Medicine Attending Physician, Professor Of Emergency Medicine, Co-Medical Director

MedStar Washington Hospital Center, Georgetown University Hospital, National Capital Poison Center